Alere i Strep A test receives marketing clearance from FDA

Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that its Alere™ i Strep A test has received marketing clearance from the U.S. Food and Drug Administration (FDA). Alere i Strep A is the first molecular test that detects Group A Streptococcus (GAS) bacteria in throat swab specimens in 8 minutes or less.

Upon receipt of this clearance from the FDA, Alere submitted an application for CLIA (Clinical Laboratory Improvement Amendments) waiver of the Alere i Strep A test. Other assays currently in development on the Alere i platform include respiratory syncytial virus (RSV), C. difficile and Chlamydia/Gonorrhoea.

"This FDA clearance brings the power of our Alere i molecular platform to the detection of Strep A. The speed and accuracy of the Alere i Strep A test empower healthcare professionals to initiate the right treatment in an actionable timeframe, which is a critical step in reducing unnecessary prescription of antibiotics and enhancing operational efficiency," said Avi Pelossof, Global President of Infectious Disease at Alere.

The Alere i molecular platform was initially cleared for marketing by the FDA for the detection and differentiation of influenza A and B virus in June 2014. In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings. Expanding the menu on the Alere i platform to include Strep A and potentially other assays increases the utility of the platform for a wider range of users. Furthermore, given the less seasonal nature of Strep A, its addition enhances the value of the platform for users on a year-round basis.

Source:

Alere Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Alere Inc.. (2019, June 17). Alere i Strep A test receives marketing clearance from FDA. News-Medical. Retrieved on June 17, 2019 from https://www.news-medical.net/news/20150402/Alere-i-Strep-A-test-receives-marketing-clearance-from-FDA.aspx.

  • MLA

    Alere Inc.. "Alere i Strep A test receives marketing clearance from FDA". News-Medical. 17 June 2019. <https://www.news-medical.net/news/20150402/Alere-i-Strep-A-test-receives-marketing-clearance-from-FDA.aspx>.

  • Chicago

    Alere Inc.. "Alere i Strep A test receives marketing clearance from FDA". News-Medical. https://www.news-medical.net/news/20150402/Alere-i-Strep-A-test-receives-marketing-clearance-from-FDA.aspx. (accessed June 17, 2019).

  • Harvard

    Alere Inc.. 2019. Alere i Strep A test receives marketing clearance from FDA. News-Medical, viewed 17 June 2019, https://www.news-medical.net/news/20150402/Alere-i-Strep-A-test-receives-marketing-clearance-from-FDA.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Alere reports net revenue of $666.9 million for fourth quarter 2014